Clinical Trials Browser

INDUSTRY × Interventional × Meningeal Carcinomatosis × Clear all

Meningeal Carcinomatosis

NCT07098806 2025-08-01

CA2024-LM-001

Meningeal Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Nervous System Diseases, Nervous System Neoplasms, Pathologic Processes, Central Nervous System Neoplasms, Meningeal Carcinomatosis

NCT00527410 2025-05-30

LMD

Phase 1 Terminated

9 enrolled

CNS

Meningeal Carcinomatosis

NCT05034497 2025-03-26

ReSPECT-LM

Phase 1 Active not recruiting

18 enrolled

CNS

Meningeal Carcinomatosis

NCT05146219 2024-12-30

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

Phase 2 Completed

29 enrolled

CNS

Brain Neoplasms, Meningeal Carcinomatosis

NCT03613181 2023-04-24

ANGLeD

Phase 3 Unknown

150 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms, Meningeal Neoplasms, Meningeal Carcinomatosis

NCT04315246 2022-07-15

177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

Phase 1/2 Withdrawn

CNS

Meningeal Carcinomatosis

NCT02228369 2021-01-05

BLOOM

Phase 1 Completed

108 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT00854867 2014-02-24

Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.

Phase 1 Completed

18 enrolled

CNS

Brain Neoplasms, Meningeal Carcinomatosis

Clinical Trials

Zorifertinib With Osimertinib for NSCLC With Meningeal Progression

CA2024-LM-001

LMD

ReSPECT-LM

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

ANGLeD

177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

BLOOM

Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.